Systemic chemotherapy for patients with advanced and metastatic bladder cancer: Current status and future directions

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  Lorusso, Vito ^a   Silvestris, N ^b  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b SANTA MARIA GORETTI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCG VACCINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ENDOSTATIN; EPIRUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PROTEIN BCL 2; TAXANE DERIVATIVE; VINBLASTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GENE THERAPY; HUMAN; KIDNEY FAILURE; METASTASIS; MUCOSA INFLAMMATION; MUSCLE METASTASIS; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; UROGENITAL TRACT CANCER;

EID: 25144489863     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi914     Document Type: Article

References (51)

1. Ahmedin J, Murray T, Ward E et al. Cancer Statistics. CA Cancer J Clin 2005; 55: 10-30.
2. Waehre H, Ous S, Klevmark B et al. A bladder cancer multi-institutional experience with total cystectomy for muscle-invasive bladder cancer. Cancer 1993; 72: 3044-3051.
3. Bales GT, Kim H, Steinberg GD. Surgical therapy for locally advanced bladder cancer. Semin Oncol 1996; 5: 603-613.
4. Chester JD, Hall GD, Forster M et al. Systemic chemotherapy for patients with bladder cancer-current controversies and future directions. Cancer Treat Rev 2004; 30: 343-358.
5. Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 2003; 4: 489-497.
6. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a phase III intergroup study of cisplatin alone of in combination with methotrexate, viblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1997; 15: 2564-2569.
7. Mead GM, Russel M, Clark P et al. A randomised trial comparing methotrexate and viblastine with cisplatin, methotrexate and vinblastine in advanced transitional cell carcinoma: Results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 1998; 78: 1067-1075.
8. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403-407.
9. Sternberg CN, Yagoda A, Scher HI et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
10. Harker WG, Meyers FJ, Freiha FS et al. Cisplatin, methotrexate, and viblastine: An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 1985; 3: 1463-1470.
11. Loehrer PJ, Einhorn LH, Elson PJ et al. A randomised comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992; 10: 1066-1073.
12. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomised trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050-1055.
13. Sternberg CN, de Mulder PH, Schornagel JH et al. Randomised phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001; 19: 2638-2646.
14. Moore MJ, Winquist EW, Murray N et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials group. J Clin Oncol 1999; 17: 2876-2881.
15. Kaufman D, Raghavan D, Carducci M et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin oncol 2000; 18: 1921-1927.
16. Von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomised, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
17. Petroli R, Freudiani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomised phase II study. Cancer 1996; 77: 344-351.
18. Carteni GD, Crucitta L, Martoni E et al. Phase II randomised trial of gemcitabine plus cisplatin and gemcitabine plus carboplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol 2003; 22: 384 (Abstr 1543).
19. Fuchs DA, Johnson RK. Cytologic evidence that Taxol, antineoplastic agent from Taxus Brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978; 62: 1219-1222.
20. Niell HB, Rangel C, Miller A et al. The activity of antimicrotubular agents in human bladder tumor cell lines (HBTCL). Proc Am Assoc Cancer Res 1993; 34: 202 (Abstr 1207).
21. Rangel C, Niell H, Miller A et al. Taxol and taxotere in bladder cancer: In vitro activity and urine stability. Cancer Chem Phar 1994; 33: 460-464.
22. Murphy BA, Johnson DR, Smith J et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc Am Soc Clin Oncol 1996; 15: 245 (Abstr 617).
23. Dreicer R, Roth B, Lipsitz S et al. E2895 cisplatin and paclitaxel in advanced carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 1998; 17: 320a (Abstr 1233).
24. Burch PA, Richardson RL, Cha SS et al. Phase II trial combination paclitaxel and cisplatin in advanced urothelial carcinoma. Proc Am Soc Clin Oncol 1999; 18: 329a (Abstr 1266).
25. Bellmunt J, Guillem V, Paz-Ares L et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 2000; 18: 3247-3255.
26. Bellmunt J, Albanell J, Paz-Ares L et al. Pre-treatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin and gemcitabine. Cancer 2002; 95: 751-757.
27. Bajorin DF, McCaffrey JA, Dodd PM et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules. Cancer 2000; 88: 1671-1678.
28. Hussain M, Vaishampayan U, Du W et al. Combination paclitaxel, carboplatin and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19: 2527-2533.
29. Lorusso V, Crucitta E, Silvestris N et al. Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium. Oncol Rep 2005; 13: 283-287.
30. Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol 2004; 16: 257-262.
31. Sternberg CN. Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. Semin Oncol 1996; 23: 621-632.
32. Neoadjuvant cisplatin, methotrexate, and viblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. International collaboration of trialists. Lancet 1999; 354: 533-540.
33. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 2003; 361: 1927-1934.
34. Grossman HB, Natale RB, Taugen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866.
35. Winquist E, Kirchner TS, Segal R et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder a systematic review and meta-analysis. J Urol 2004; 171: 561-569.
36. Skinner DG, Daniels JR, Russel CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 1991; 145: 459-464.
37. Stockle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995; 153: 47-52.
38. Freiha F, Reese J, Torti FM. A randomised trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 495-499.
39. Otto T, Borgermann C, Krege S et al. Radical cystectomy +/- adjuvant chemotherapy in bladder cancer: A randomised phase III study. J Urol 2001; 165: 279.
40. Sternberg CN. Chemotherapy for local treatment of bladder cancer. Semin Radiat Oncol 2005; 15: 60-65.
41. Cote RJ, Esrig D, Groshan S et al. p53 status and treatment of bladder cancer. Nature 1997; 385: 123-125.
42. Gospodarowicz MK, Warde PR. A critical review of the role of definitive radiation therapy in bladder cancer. Semin Urol 1993; 4: 214-226.
43. Angulo JC, Sanchez-Chapado M, Lopez JI et al. Primary cisplatin, methotrexate and viblastine aiming at bladder preservation in invasive bladder cancer: Multivariate analysis on prognostic factors. J Urol 1996; 155: 1897-1902.
44. Tester W, Caplan R, Heaney J et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996; 14: 119-126.
45. Shipley WV, Kaufman DS, Zehr E et al. Long-term outcome of patients treated for muscle-invasive bladder cancer by tri-modality therapy. Urology 2002; 60: 62-68.
46. Rodel C, Gerhard G, Grabenbauer GG et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002; 20: 3061-3071.
47. Shah JB, McKiernan JM. Novel therapeutics in the treatment of bladder cancer. Curr Opin Urol 2004; 14: 287-293.
48. Du Z, Haou S. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. J Urol 2003; 17: 2000-2003.
49. Inoue K, Chikazawa M, Fukata S et al. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transition cell carcinoma in the urinary bladder. Clin Cancer Res 2002; 8: 2389-2398.
50. Hong JH, Lee E, Hong J et al. Antisense Bcl-2 oligonucleotide in cisplati-resistant bladder cancer cell lines. BJU Int 2002; 90: 113-117.
51. Latif Z, Watters AD, Dunn I et al. HER2/neu gene amplification and protein overexpression in G3 T2 transitional cell carcinoma of the bladder: A role for anti-HER2 therapy? Eur J Cancer 2004; 40: 56-63.